Get the Stockscreener App
6.09
9.93%
0.55
Eupraxia Pharmaceuticals Inc stock is traded at $6.09, with a volume of 365.93K.
It is up +9.93% in the last 24 hours and up +4.10% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$5.54
Open:
$5.65
24h Volume:
365.93K
Relative Volume:
5.68
Market Cap:
$219.00M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-7.9091
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
+10.13%
1M Performance:
+4.10%
6M Performance:
+52.06%
1Y Performance:
+96.45%
1-Day Range:
$5.47
$6.10
1-Week Range:
$5.33
$6.10
52-Week Range:
$2.6801
$7.19
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.09 | 280.30M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Is Eupraxia Pharmaceuticals Inc. stock ready for a breakoutWeekly Trading Summary & AI Forecast Swing Trade Picks - newser.com
Volatility clustering patterns for Eupraxia Pharmaceuticals Inc.July 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Is Eupraxia Pharmaceuticals Inc. stock bottoming outTrade Exit Summary & Long Hold Capital Preservation Tips - newser.com
Why Eupraxia Pharmaceuticals Inc. stock is trending among retail tradersTrade Risk Report & Community Verified Swing Trade Signals - newser.com
Can Eupraxia Pharmaceuticals Inc. stock continue upward trendWeekly Loss Report & Reliable Price Breakout Alerts - newser.com
Will Eupraxia Pharmaceuticals Inc. (X43) stock outperform global peersMarket Risk Analysis & Reliable Price Action Trade Plans - newser.com
Is Eupraxia Pharmaceuticals Inc. stock reversal real or fake2025 Trade Ideas & Safe Entry Momentum Stock Tips - newser.com
Using data filters to optimize entry into Eupraxia Pharmaceuticals Inc.2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
Eupraxia Pharmaceuticals Inc. stock prediction for this weekPortfolio Growth Summary & Community Verified Trade Alerts - newser.com
(EPRX.WT.A) Stock Analysis and Trading Signals - news.stocktradersdaily.com
Will Eupraxia Pharmaceuticals Inc. stock see insider buyingWeekly Loss Report & Weekly Hot Stock Watchlists - newser.com
Is Eupraxia Pharmaceuticals Inc. reversing from oversold territoryNew Guidance & High Accuracy Trade Signal Alerts - newser.com
Regression analysis insights on Eupraxia Pharmaceuticals Inc. performanceJuly 2025 Market Mood & Weekly High Potential Stock Alerts - newser.com
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
(EPRX) Stock Trading Blueprint (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc. stock trend forecastM&A Rumor & Safe Entry Trade Reports - newser.com
Research Analysts Offer Predictions for EPRX FY2025 Earnings - MarketBeat
Strategies to average down on Eupraxia Pharmaceuticals Inc.July 2025 Earnings & Reliable Trade Execution Plans - newser.com
Eupraxia Pharmaceuticals Inc. (EPRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded to Strong-Buy at Leede Financial - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Expected to Announce Earnings on Thursday - MarketBeat
(EPRX.WT.A) Optimized Trading Opportunities - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc. (EPRX.TO) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial - TipRanks
This analyst loves Eupraxia Pharmaceuticals - Cantech Letter
(EPRX) Trading Strategy and Analysis (EPRX:CA) - news.stocktradersdaily.com
Chart based analysis of Eupraxia Pharmaceuticals Inc. trendsWeekly Investment Report & AI Enhanced Trade Execution Alerts - newser.com
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):